Polycythemia Vera Treatment Market Trends

Growth Drivers

• Expansion in first-line treatment: This particular treatment is frequently considered to be a part of the standard set of treatments, including surgery, which is followed by radiation and chemotherapy. In addition, it is accepted as one of the best treatments, which is positively impacting the polycythemia vera treatment market. In this regard, the September 2023 NLM article indicated that the first-line tyrosine kinase inhibitors (TKIs) therapy has been successful at a 66.2% rate. In addition, first-line platinum-specific chemotherapy has also been successful, with a rate of 43.1% and 48.6% by combining both pemetrexed and bevacizumab.
• Sudden shift towards targeted therapies: These therapies are readily designed to operate by effectively exploiting differences between healthy cells and cancer cells, thereby positively driving the polycythemia vera treatment market internationally. According to an article published by Biochemical Pharmacology in October 2022, with the adoption of targeted therapy, HER2 amplification accounted for 28% of human breast tumors, which was correlated with a high risk of relapse and death. Besides, a 10-year randomization process, the disease-free survival rate was 69% for cohorts after receiving 2 years of trastuzumab, thus suitable for uplifting the market.
• Innovation in drug formulations: The aspect of drug formulation is gaining increased importance in modern medicine, which is further turning raw active ingredients into effective and combinable therapies, thus boosting the polycythemia vera treatment market. According to an article published by the MedRxiv Organization in February 2024, an overall 20,398 CTPs, which corresponds to 9,682 unique molecular entities for aiding 910 disease classes, have been readily defined by the WHO, thus denoting a huge growth opportunity for the overall market internationally.

Polycythemia Diagnosis Categories Driving the Market Demand (2023)

Source: NLM

Medical Treatment Boosting the Polycythemia Vera Treatment Market

Source: NLM

Challenges

• Government negotiations and price controls: The US Inflation Reduction Act (IRA) effectively represents a paradigm shift, which has permitted Medicare to successfully negotiate drug prices directly. For the polycythemia vera treatment market, a particular therapy chosen for negotiation is projected to experience a mandatory price, which is significantly below its market rate, thereby drastically diminishing the revenue potential. Besides, the Congressional Budget Office stated that this will effectively reduce federal spending, resulting loss of revenue for manufacturers.
• Cost-sharing and patient affordability: Even after achieving insurance coverage, co-insurance, and high deductibles can leave patients with disabling out-of-pocket expenses for special tier medications. This has led to non-adherence, worsened health outcomes, and prescription abandonment, thereby negatively impacting the polycythemia vera treatment market internationally. In addition, this harms patients, as well as undermines a drug’s real-world effectiveness and valuable story. However, to overcome this issue, manufacturers are recommended to fund ongoing patient assistance programs that can readily cover these expenses.